



PROGRAM
27. Årsmøde Fredag d. 2. maj 2014
Dansk Selskab for Cancerforskning

- 08.00-09.00 Registration, posters on the boards and coffee
- 09.00-09.05 Welcome and practical information by the Chairman, Dr. Ulrik Lassen
- SESSION I Basic and Translational Research**
Chairmen: **Berthe Marie Willumsen**, Professor, mso, Biologisk Institut, Cell and Developmental Biology, and **Niels Behrendt**, Ph.d., DSc., The Finsen Laboratory, Copenhagen.
- 09.05-09.20 **Jarid2 supports the maintenance of leukemic stem cells**
Anne-Katrine Frank^{*1,2,3}, Anton Willer^{*1,2,3}, Karl Agger^{2,3}, Kristian Helin^{2,3}, Bo Porse^{1,2,3}
¹Finsen Laboratoriet, Rigshospitalet, University of Copenhagen, Denmark,
²Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Denmark,
³Danish Stem Cell Centre (DanStem), University of Copenhagen, Denmark
*equal contribution
- 09.20-09.35 **Autocrine VEGFC-VEGFR2 signaling is of importance for the growth of Glioblastoma Multiforme**
Michaelsen SR¹, Nedergaard MK², Pedersen P¹, Stockhausen M-T¹ and Poulsen HS¹
¹Department of Radiation Biology, Oncology Clinic, The Finsen Center, Rigshospitalet, Copenhagen, Denmark
²Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
- 09.35-09.50 **The role of the actinomyosin apparatus in glioma stem cell invasion and differentiation**
Peter Bavngaard Thrane¹, Anette Høye¹, Lukram Babloo Singh¹, Lara Perryman¹, Chris Denis Madsen¹, Thomas Cox¹, Marie Stockhausen², Hans Skovgaard Poulsen² and Janine Erler¹
¹Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Ole Maaløes Vej 5, 4. 2200 Copenhagen N, Denmark
²Dept. of Radiation Biology, The Finsencent, section 6321, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark
- 09.50-10.05 **5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies**
Anne Ortvad Gang^{*1}, **Thomas Mørch Frøsig**^{*1,2}, Marie Klinge Brimnes¹, Rikke Lyngaa¹, Marianne Bach Treppendahl³, Kirsten Grønbæk³, Inge Høgh Dufva⁴, Per thor Straten¹, Sine Reker Hadrup¹
***These authors contributed equally to this work.**
¹Center for Cancer Immunoterapi, Hæmatologisk Afdeling, Herlev Universitetshospital, ²Institut for Lægemiddeludvikling of Farmakologi, Sundhedsvidenskabeligt Fakultet, Københavns Universitet, ³Hæmatologisk Afdeling, Rigshospitalet.
- 10.05-10.20 **Simultaneous inhibition of EGFR, HER2 and HER3 by an antibody mixture provides broad and potent tumor inhibition**
Thomas T. Poulsen, Mikkel W. Pedersen, Helle J. Jacobsen, Ida Kjær, Klaus Koefoed, Jette W. Sen, Dietmar Weilguny, Bolette Bjerregaard, Christina R. Andersen, Ivan D. Horak, Michael Kragh and Johan Lantto
Symphogen A/S, Elektrovej Bygning 375, 2800 Lyngby
- 10.20-10.50 **POSTERS & Coffee**



10.50-11.20

Translational Research (invited lecture)

"Translational research on endocrine resistant breast cancer"

Anne E. Lykkesfeldt, Ph.D., D.Sc., Head of Breast Cancer Group, Cell Death and Metabolism, Danish Cancer Society Research Center.

11.20-12.00

Gårdejer Ingemann Petersen og hustrus Foundation, Honory price and talk

12.00-13.00

LUNCH

13.00-13.30

Coffee/POSTERS

13.30-14.30

The Danish Cancer Society Lecture:

"Circulating Tumor Cells".

Caroline Dive, Professor of Pharmacology and Pharmacy, School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, UK.

Introduction by MD, Ph.D. Ulrik Lassen.

14.30-15.00

POSTERS & Coffee

SESSION II

Translational and Clinical Research

Chairmen:

Kirsten Grønbæk, MD, Professor, DMSci, Dept of Hematology, Rigshospitalet, and
Morten Mau-Sørensen, MD, Ph.d., Dept. of Oncology, Rigshospitalet.

15:00-15.30

Translational Research (invited lecture)

"Non-invasive analysis of circulating tumor DNA enables earlier detection of recurrence and assessment of resistance to adjuvant chemotherapy during clinical follow-up after resection of colorectal cancer"

Claus Lindbjerg Andersen, Professor, Institut for Klinisk Medicin, Molekylær Medicinsk afdeling (MOMA)

15.30-15.45

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen resistant breast cancer cells

Astrid Munk Pedersen, S Thrane, MBH Thomsen, AE Lykkesfeldt and CW Yde

Brystkræftgruppen, Celledød & Metabolisme, Kræftens Bekæmpelse, Strandboulevarden 49, 2100 Ø

15.45-16:00

Metformin and other biguanides as anticancer drugs: Comparison of in vivo bioavailability and in vitro sensitivity

Ane B Iversen¹, Christian Garm², Steen Jakobsen³, Brita S Sørensen¹, Niels Jessen⁴, Jørgen Frøkiær³, Jens Overgaard¹, Michael R. Horsman¹ and Morten Busk¹

1) Afdeling for Eksperimentel Klinisk Onkologi, Aarhus Universitetshospital, Nørrebrogade 44, bygning 5, 8000 Århus C

2) Institut for Molekylærbiologi og Genetik, C.F Møllers Allé 3, bygning 1130, 8000 Aarhus C

3) PET centre, Aarhus Universitetshospital, Nørrebrogade 44, bygning 3, 8000 Århus C

4) Molekylær Medicinsk Afdeling, Aarhus Universitetshospital, Brendstrupgårdsvej 100, 8200 Aarhus N

16:00-16.15

Determination of Differential Transcription Start Sites in Transcription Factors during B-Cell Differentiation in Normal Tissues and Diffuse Large B-cell Lymphoma

Julie Støve Bødker¹, Malene Krag Kjeldsen¹, Maria Bro Kloster¹, Maria Rodrigo-Domingo^{1,2}, Anders Ellern Bilgrau^{1,2}, Preben Johansen³, Alexander Schmitz¹, Hans E. Johnsen¹, Martin Bøgsted^{1,2,4}, Karen Dybkaer^{1,4}

¹ Hæmatologisk Afdeling, Aalborg Universitets Hospital, Forskningsens Hus, Sdr. Skovvej 15, 9000 Aalborg

² Institut for Matematiske fag, Aalborg Universitet, Fredrik Bajers Vej 7G, 9220 Aalborg Ø

³ Patologisk Institut, Aalborg Universitetshospital, Ladegårdsgade 3, 9100 Aalborg

⁴ Klinisk Institut, Det Sundhedsvidenskabelige Fakultet, Aalborg Universitet, Sdr. Skovvej 11, 2. sal, 9000 Aalborg



- 16.15-16.30 **Copenhagen Prospective Personalized Oncology (CoPPO): Sequencing and array-based pipeline for selection of patients to Phase 1 studies**
*Tuxen IV*¹, Joenson L³, Santoni-Rugiu E², Nielsen FC³, Vikeså J³, Mau-Sørensen M¹, Lassen U¹
¹Onkologisk klinik, Rigshospitalet, Blegdamsvej 9, 2100 København Ø
²Patologifdelingen, Rigshospitalet, Blegdamsvej 9, 2100 København Ø
³Genomisk medicin, Rigshospitalet, Blegdamsvej 9, 2100 København Ø
- 16.30-16.45 **Metastatic colorectal cancer patients with KRAS mutated tumors and high plasma TIMP-1 level seems to benefit from EGFR-inhibition therapy: results from the NORDIC VII Study**
*Line S. Tarpgaard*¹, Ib J. Christensen², Jose M. A. Moreira³, Tormod K. Guren⁴, Bengt Glimelius⁵, Halfdan Sorbye⁶, Tone Ikdal⁴, Elin H. Kure⁴, Kjell M. Tveit⁴, Hans Jørgen Nielsen⁷, Per Pfeiffer¹, and Nils Brünner³
¹Onkologisk Afdeling, Odense Universitetshospital og klinisk Institut, Syddansk Universitet, Odense, Denmark, ²Finsenslaboratoriet, Rigshospitalet og Biotech Research and Innovation Center (BRIC), Københavns Universitet, København, Danmark, Institut for Veterinær Sygdomsbiologi, Københavns Universitet, København, Danmark, ⁴Kreftcenteret, Oslo Universitetssykehus, Oslo, Norge, ⁵Institutionen för radiologi, onkologi och strålningsvetenskap, Uppsala Universitet, Uppsala og Institutionen för onkologi-Pathology, Karolinska Institute, Stockholm, Sverige, ⁶Avdeling for Kreftbehandling og medisinsk fysikk, Haukeland Universitetssjukehus, Bergen, Norge, ⁷Gastroenheden, Hvidovre Hospital, Københavns Universitets Hospital, Hvidovre, Denmark
- 16.45-17.05 **Refreshments**
- 17.05-17.20 **PRICE FOR BEST TALK AND POSTER**
- 17.20-17.30 **Adjourn**
- 17.30-18.00 **General assembly**
- 18.00 **DINNER**